Trial Profile
Phase I/II Study on Intratumor Dendritic Cell Injection Immunotherapy Using Immature Dendritic Cells With S Pyogenes Preparation (OK-432) for Patients With Resectable Pancreatic Cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Sep 2011
Price :
$35
*
At a glance
- Drugs Pancreatic cancer vaccine (Primary) ; Picibanil (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 29 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Dec 2008 New trial record.